

CANADIAN CANCER TRIALS GROUP

**LOCALIZED PROSTATE**

GU DISEASE ORIENTED GROUP MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON

ROOM: WREN

SATURDAY APRIL 30<sup>TH</sup>, 2016, 7:00 AM – 8:00 AM

CO-CHAIRS: A. LOBLAW & N. FLESHNER

SENIOR INVESTIGATOR: FRANCISCO VERA-BADILLO

STUDY COORDINATOR: ALEXANDER MONTENEGRO

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- *To understand and address, through clinical and translational research, the disease burden associated with localized prostate cancer in Canada.*
- *To review recent developments in the understanding of molecular biology and new therapeutics as these relate to localized prostate cancer.*
- *To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group and/or by national/ international collaborators.*
- *To provide mentoring opportunities for investigators new to clinical trial research.*
- *To understand and apply new clinical trial methodologies in the field of clinical research related to localized prostate cancer.*

---

**7:00 am Welcome**

**A. Loblaw**

**CCTG Lead Approved TRIALS**

**7:05 am PR.19:** A randomized phase II trial evaluating treatment outcome, acute and long-term toxicity of High Dose Rate Brachytherapy (HDRB) and Low Dose Rate Brachytherapy (LDRB) as monotherapy in localized prostate cancer.

**L. Hathout**

**New Trial Proposals**

**7:15 am SWOG** Randomized phase III trial of best standard therapy or best standard therapy plus surgical treatment of the primary tumor in metastatic prostate cancer.

**K. Chi**

**7:25 am TOPSIDE:** Randomized phase II study: Treatment of the prostate and intermittent androgen deprivation in metastatic prostate cancer

**H. Quon / P. Cheung**

*continued on next page ...*

**7:35 am PREMIUM:** Radiotherapy +/- metformin

**N. Usmani**

**New TRIAL CONCEPTS**

**7:45 am ECOG-ACRIN ERADICATE:** Early Intervention after Radical Prostatectomy with Enzalutamide or Docetaxel versus Androgen Deprivation Therapy in Men at Highest Risk of Metastasis by Genomic Stratification.

**A. Loblaw**

**7:50 am** Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) initiative

**C. Sweeney**

**8:00 am** Meeting Adjourned